DHDaniel A. Heller

Daniel A. Heller

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Daniel A. Heller has a total of 720 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Senescence-directed nanotherapy ameliorates fibrosis and overcomes immune exclusion in cancer

    by Clemens Hinterleitner, Valentin J. A. Barthet, Hailey V. Goldberg, Kristen C. Vogt, Ana Marie Perea, Logan R. Hillger, Stephen Ruiz, Domhnall McHugh, Yu-Jui Ho, Almudena Chaves-Perez, et al.

    Fibrotic remodeling of tissues and tumors establishes immunosuppressive microenvironments that drive organ dysfunction and, in cancer, limit response to immunotherapy. Senescent-like cells are conserved drivers of fibrosis and therapeutic targets, yet their functional heterogeneity complicates therapeutic intervention. Here, we show that P-selectin is expressed by a subset of senescent-like cells in fibrotic tissues and tumors. Leveraging fucoidan-based nanoparticles that bind P-selectin, we developed senescence-modulating nanoparticles (SMNPs) to selectively target these disease-associated states. SMNPs exerted potent antifibrotic and immunomodulatory effects while improving the therapeutic index. Mechanistically, we identified a pathogenic, immunosuppressive macrophage population as a functional target in vivo. In fibrotic tumors, niche remodeling restored immune infiltration and sensitized tumors to immune checkpoint–based therapies. These findings establish SMNPs as a generalizable strategy to target pathogenic senescent cell subsets across fibrosis and cancer.


  • Artificial intelligence and machine learning in nanoparticle drug delivery systems

    by Magdalini Panagiotakopoulou, Anita Goren, Daniel Reker, Avi Schroeder, Christine Allen, Daniel A. Heller


  • Machine Perception-Based Prediction of Pregnancy Loss

    by Jaina Sarris Wollowitz, Pietro Bortoletto, Dana Goerzen, Daylon James, Mijin Kim, Daniel A. Heller

    Over 15% of pregnancies result in miscarriage, yet no reliable indicators exist to inform clinicians or patients of the risk of pregnancy loss. Here, we established a liquid biopsy platform using machine learning to predict the risk of pregnancy loss, incorporating existing clinical biomarkers in combination with spectroscopic data from an optical nanosensor array. Biomarker and array data from sera of over 850 in vitro fertilization patients, collected two weeks after single euploid embryo transfer, were used to train and validate machine learning models to differentiate live birth from two categories of pregnancy loss: biochemical pregnancy or miscarriage. The combination of clinical biomarkers and nanosensor array responses led to the best prediction models, compared to either dataset alone, resulting in positive predictive values of 97.2% and 87.5% for biochemical pregnancy and miscarriage, respectively. These results suggest that a combination of known and unknown serum biomarkers from patients at the time of their first positive pregnancy test can provide a clinically meaningful aggregate prediction of risk of both early and later stage pregnancy loss.

  • Quantum Well Nanosensors for Diagnostic Applications

    by Daniel A. Heller

    Quantum well nanosensors (QWNs) are composed of quantum-well defects (QWDs) on single-walled carbon nanotubes (SWCNTs). SWCNTs are highly sensitive to their local environment and are developed into electronic/electrochemical or optical sensors. QWDs introduce new chemical sensitivities on SWCNTs. We are developing arrays of QWNs for the investigation and detection of cancers and other conditions using AI-enabled methods. Via machine learning algorithms, we built prediction models of nanosensor responses that can reliably identify several cancer and non-cancer conditions, and we have expanded this approach to indications without known biomarkers, providing a general method to detect and identify diseases.

  • Non-Invasive Spectroscopic Detection of Brain Tumors Based on Chemically Modified Carbon Nanotube Array

    by Dana Goerzen, Mijin Kim, Jaina Sarris Wollowitz, Daniel A. Heller

    The detection and identification of intracranial tumours is limited by the lack of accurate biomarkers and requires invasive biopsy procedures. We investigated a machine perception liquid biopsy approach to detect and identify intracranial tumours from peripheral blood and to discover biomarkers responsible for the predictions. Quantum well defect-modified single-walled carbon nanotubes stabilized with single-stranded DNA, interrogating 739 plasma samples from brain tumour patients, were used to train and validate machine-learning models to detect intracranial tumours with 98% accuracy and identify tumour type. The protein corona of the top model-contributing nanosensor was interrogated using quantitative proteomics, resulting in the identification of tumour ecosystem-secreted factors, both previously reported and newly discovered, originating from intracranial tumour cells, the tumour microenvironment and the innate immune system of patients with glioblastoma and meningioma. Newly discovered factors elicited linear nanosensor responses and were elevated in one or both tumour types, matching the original protein corona enrichment. This investigation reveals that a perception-based detection of disease in blood can identify biomarkers responsible for the signal and also amplify cancer detection signals by detecting factors beyond tumour cells, thereby recruiting the entire tumour ecosystem for cancer diagnosis.

  • Boronic Acid Handle Chemistry for Highly Tunable Functionalization of Single-Walled Carbon Nanotubes

    by Alec Goffin, Stanislav Piletsky, Erin Elizabeth Keblish, Daniel A. Heller

    Single-walled carbon nanotubes (SWCNTs) possess unique optical and electronic properties that make them promising materials for applications in chemical sensing, imaging, and optoelectronics. Covalent functionalization of SWCNT introduces localized sp³ defects onto the sp2 carbon lattice, which can enhance these properties and enable the attachment of functional molecules such as catalysts or biomolecules. However, the standard approach of aryl diazonium induced defects suffers from key limitations, including harsh reaction conditions, poor control over the degree of functionalization that compromises reproducibility, and reliance on a relatively small set of commercially available diazonium salts. These constraints restrict chemical diversity and hinder systematic investigation of defect structure–property relationships.

  • Machine Perception Liquid Biopsy via Quantum Well Nanosensors

    by Daniel A. Heller, Dana Goerzen, Mijin Kim, Jaina Sarris Wollowitz, Erin Elizabeth Keblish, Stanislav Piletsky, Alec Goffin

    A liquid biopsy is a blood test that provides similar kinds of molecular information as solid tissue biopsies, potentially enabling cancer diagnosis and monitoring. Most existing liquid biopsy technologies use molecular changes to circulating DNA, normally circulating tumor DNA (ctDNA). However, not all cancers produce sufficient ctDNA for diagnosis, especially in early-stage cancers. We are developing quantum well nanosensors (QWNs) composed of quantum-well defects (QWDs) on single-walled carbon nanotubes (SWCNTs) to enable new research and diagnostic methods for cancers and other indications. New synthetic methods for QWD-modified SWCNTs (color center nanotubes, CCNTs, or quantum-well defect nanotubes (QWNTs)) can enable new sensitivities of QWNs, improve yield and simplify processing. We are developing arrays of QWNs for the investigation and detection of cancers and other conditions using AI-enabled methods. Via machine learning algorithms, we built prediction models of nanosensor responses that can reliably identify several cancer and non-cancer conditions, and we have expanded this approach to indications without known biomarkers, providing a general method to identify diseases. Also, by eluting and measuring the proteins captured and enriched on the QWNs (the protein corona) via mass spectrometry, QWNs enabled the discovery of new biomarkers responsible for their optical responses.

  • New Strategies for the Controlled Functionalization of Carbon Nanotubes Resulting in Quantum Well Defects

    by Stanislav Piletsky, Alec Goffin, Erin Elizabeth Keblish, Daniel A. Heller

    Covalent functionalization of single-walled carbon nanotubes (SWCNTs) enables controlled modulation of their optical and electronic properties. The deliberate introduction of localized sp3 defects creates emissive “quantum wells” that trap excitons and give rise to red-shifted near-infrared fluorescence. These defect-engineered nanotubes have attracted significant interest for applications in biosensing, bioimaging, and quantum optics. However, most established methods for generating such defects rely on a limited set of pre-activated reagents, restricting chemical diversity and constraining control over defect structure and electronic coupling.

  • Enhancement of Arylated Carbon Nanotube Fluorescence

    by Erin Elizabeth Keblish, Stanislav Piletsky, Alec Goffin, Daniel A. Heller

    Covalently modified single walled carbon nanotubes, also known as color center nanotubes (CCNTs), can be used for a wide range of applications, including in sensing and disease diagnostics. These covalent modifications change the innate photoluminescence of SWCNTs generating new emission peaks (E11 - and E11 *-) in the fluorescence spectra that are redshifted from the native emission peak (E11). By modifying the surface of SWNCTs with different compounds, libraries of chemically diverse CCNTs can be generated. Many reactions have been developed to functionalize SWCNTs with alkyl and aryl defects, with arylation commonly achieved using diazonium salts. We have a found a novel synthesis method for arylated CCNTs that results in bright emission spectra with sharp emission peaks for the E11 - and E11 *-. These enhanced fluorescence peaks will enable the development of more robust and sensitive diagnostic systems.

  • (Invited) Quantum Well Nanosensor Synthesis and Applications In Biomedicine

    by Daniel A. Heller, Stanislav Piletsky, Erin Elizabeth Keblish, Alec Goffin, Anand Jagota, YuHuang Wang, Ming Zheng, Dana Goerzen, Jaina Sarris Wollowitz

    Quantum-well defects (QWDs) on single-walled carbon nanotubes (SWCNTs) enable expanded analyte sensitization and functionalization for biosensing applications. We are developing these materials into quantum well nanosensors (QWNs) to enable new research and diagnostic methods for cancers and other indications. New synthetic methods for QWD-modified SWCNTs (color center nanotubes, CCNTs, or quantum-well defect nanotubes (QWNTs)) can enable new sensitivities of QWNs, improve yield and simplify processing. We are developing arrays of QWNs for the investigation and detection of cancers and other conditions using AI-enabled methods and mass spectrometry. Via machine learning algorithms, we built prediction models of nanosensor responses that can reliably identify several cancer and non-cancer conditions, and we have expanded this approach to indications without known biomarkers, providing a general method to identify diseases. Also, by eluting and measuring the proteins captured and enriched on the QWNs (the protein corona) via mass spectrometry, QWNs enabled the discovery of new biomarkers responsible for their optical responses.